QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.024273v1 70/5/1621    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gao, H. Articles by Wang, Z. Search for Related Content PubMed PubMed Citation Articles by Gao, H. Articles by Wang, Z.

A Single Decoy Oligodeoxynucleotides Targeting Multiple Oncoproteins Produces Strong Anticancer Effects

Research Center, Montreal Heart Institute, Montreal, Quebec, Canada (H.G., J.X., Q.S., H.L., L.Y., H.W., Z.W.); Department of Medicine, University of Montreal, Montreal, Quebec, Canada (Z.W.); and Department of Pharmacology (State-Province Key Lab of China) (Y.B., B.Y.) and Institute of Cardiovascular Research (J.X., H.L., B.Y., Z.W.), Harbin Medical University, Harbin, People's Republic of China

Cancer in general is a multifactorial process. Targeting a single factor may not be optimal in therapy, because single agents are limited by incomplete efficacy and dose-limiting adverse effects. Combination pharmacotherapy or "drug cocktail" therapy has value against many diseases, including cancers. We report an innovative decoy oligodeoxynucleotide (dODN) technology that we term complex decoy oligodeoxynucleotide (cdODNs) in which multiple cis elements are engineered into single dODNs attacking multiple target transcription factors, mimicking the drug cocktail approach. We designed dODNs targeting NF-B, E2F, and Stat3 separately and a cdODN targeting NF-B, E2F, and Stat3 concomitantly. We evaluated effects of this cdODN on expression of cancer-related genes, viability of human cancer cell lines, and in vivo tumor growth in nude mice. The cdODN targeting all NF-B, E2F, and Stat3 together demonstrated enhancement of efficacy of more than 2-fold and increases in potency of 2 orders of magnitude compared with each of the dODNs or the combination of all three dODNs. The cdODN also showed earlier onset and longer-lasting action. Most strikingly, the cdODN acquired the ability to attack multiple molecules critical to cancer progression via multiple mechanisms, leading to elimination of regression. Real-time reverse transcription-polymerase chain reaction revealed that the cdODNs knocked down expression of the genes regulated by the target transcription factors. The cdODN strategy offers resourceful combinations of varying cis elements for concomitantly targeting multiple molecules in cancer biological processes and opens the door to "one-drug, multiple-target" therapy for a broad range of human cancers.

Received for publication March 8, 2006.

Accepted for publication August 25, 2006.

Address correspondence to: Dr. Zhiguo Wang, Research Center, Montreal Heart Institute, 5000 Belanger East, Montreal, QC H1T 1C8 Canada. E-mail: wz.email{at}gmail.com

This article has been cited by other articles:

				Y. Lu, Y. Zhang, H. Shan, Z. Pan, X. Li, B. Li, C. Xu, B. Zhang, F. Zhang, D. Dong, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection Cardiovasc Res, July 31, 2009; (2009) cvp232v2. [Abstract] [Full Text] [PDF]

				L. Penolazzi, M. Zennaro, E. Lambertini, E. Tavanti, E. Torreggiani, R. Gambari, and R. Piva Induction of Estrogen Receptor {alpha} Expression with Decoy Oligonucleotide Targeted to NFATc1 Binding Sites in Osteoblasts Mol. Pharmacol., June 1, 2007; 71(6): 1457 - 1462. [Abstract] [Full Text] [PDF]